

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	I	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/751,302	10/751,302 01/02/2004		Guilherme L. Indig	032026-0769	8802
23524	7590	04/19/2006		EXAMINER	
FOLEY &			GRAFFEO, MICHEL		
150 EAST C P.O. BOX 14		STREET	ART UNIT	PAPER NUMBER	
MADISON, WI 53701-1497				1614	
				DATE MAILED: 04/19/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)						
Office Action Summany	10/751,302	INDIG, GUILHERME L.						
Office Action Summary	Examiner	Art Unit						
	Michel Graffeo	1614						
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status								
1) Responsive to communication(s) filed on 01 De	ecember 2005.							
, <u> </u>	action is non-final.							
·—	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims								
4)⊠ Claim(s) <u>1-8 and 10</u> is/are pending in the application.								
4a) Of the above claim(s) is/are withdrawn from consideration.								
5) Claim(s) is/are allowed.								
6)⊠ Claim(s) <u>1-8 and 10</u> is/are rejected.								
7) Claim(s) is/are objected to.								
8) Claim(s) are subject to restriction and/or	election requirement.							
Application Papers								
9) The specification is objected to by the Examiner.								
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority under 35 U.S.C. § 119	•							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
Attachment(s) 1) ☑ Notice of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO_413)						
2) Notice of References Cited (P10-892) Notice of Draftsperson's Patent Drawing Review (PT0-948)	4) 🔲 Interview Summary Paper No(s)/Mail Da							
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date <u>1 Dec 05</u> .		atent Application (PTO-152)						

Art Unit: 1614

DETAILED ACTION

Status of Action

Claims 1-8 and 10 are pending and examined.

Applicant has amended claim 6, canceled claim 9 and provided arguments for the patentability of claims 1-8 and 10 in the response filed 1 December 2005.

Applicant's arguments, see response, filed 1 December 2005, have been fully considered and are persuasive to the extent that the Indig reference is removed as a reference under 35 USC §102 and 35 USC §103 and Fiedorowicz is removed as a reference under 35 USC §102. Therefore, the rejection of claims 1-4 and 6-8 and 10 under 35 USC §112 and 35 USC §102, have been withdrawn as well as the Double Patenting rejection in light of the approved Terminal Disclaimer. However, upon further consideration, a new ground(s) of rejection is made.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Rejections - 35 USC § 103

Claims 1-8 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fiedorowicz et al. (cited by Applicant on the IDS filed 20 May 2004 page 2 of 6, #12) in view of Reed et al. The Tuor-inhibitory Activity of Diaryl-and Triarylmethane Dyes. Cancer Research (1953), 13, 130-6 in view of Indig G.L (cited by Applicant on the IDS filed 1 December 2005 page 3 of 6, #6).

Art Unit: 1614

Fiedorowicz discloses (in current claims 1-8 and 10; see abstract, pages 857-858) a method of purging leukemia cells from human blood cells by contacting the mixture with a photoreactive compound and exposing it to radiation to photoactivate the compound.

Fiedorowicz does not show the compound of the instant claims.

Reed et al. teach that Crystal Violet, for example, has anti-tumor properties and of 235 dye compounds was among the most reactive anti-tumor compounds (in current claims 1-8 and 10; see page 135).

Indig teaches that photoreactive compounds such as Crystal Violet (in current claims 1-8 and 10; see page 233) are efficacious in the treatment of neoplastic diseases.

One of ordinary skill in the art would have been motivated to combine the above references and as combined teach the claimed invention as claimed. One of ordinary skill in the art would have been motivated to combine the above references primarily because Indig teaches that photoreactive compounds such as Crystal Violet are efficacious in the treatment of cancer. Fiedorowicz further teaches specific cancers that are treatable with photoreactive compounds. And finally, both Reed and Indig teach that Crystal Violet has anti-cancer properties. Thus, the combined references teach and make prima facie obvious how to use the claimed invention at the time that it was made.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the

Art Unit: 1614

unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-8 and 10 are rejected on the ground of nonstatutory double patenting over claims 1-26 of U. S. Patent No. 6,914,078 since the claims, if allowed, would improperly extend the "right to exclude" already granted in the patent.

The subject matter claimed in the instant application is fully claimed in the patent and is covered by the patent since the patent and the application are claiming common subject matter, as follows: a method of purging/killing cancer cells comprising contacting the cells with a compound having the following general structure:

Application/Control Number: 10/751,302

Art Unit: 1614

Response to Arguments - 35 USC § 112

Applicant's arguments filed 1 December 2005 have been fully considered and are persuasive for the reasons of record.

Response to Arguments - 35 USC § 102

Applicant's arguments filed 1 December 2005 have been fully considered and are persuasive for the reasons of record.

Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michel Graffeo whose telephone number is 571-272-8505. The examiner can normally be reached on 9am to 5:30pm Monday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/751,302

Art Unit: 1614

Page 5

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

13 April 2006 MG

no

CHRISTOPHER S. F. LOW
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1603

Bruce M. Kisliuk, Director Technology Center 1600